ATC code None PubChem CID 25105689 UNII ON5S6N53JS Molar mass 278.3898 g/mol | CAS Number 1092977-61-1 ChemSpider 44208827 Formula C16H26N2O2 | |
 | ||
Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[1]
References
Evenamide Wikipedia(Text) CC BY-SA